PRNewsWire
15 May 2026, 00:15 UTC · 24w ago
Verdict
Headline takes no side. We score REPL −1.00 across four claims — strongly bearish.
−1.00strongly bearish
More negative than 99% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Replimune received a Complete Response Letter from the FDA for its Biologics License Application for RP1 in combination with nivolumab for the treatment of advanced melanoma.
More negative than 99% of claims this week
There is disagreement between Replimune and the FDA regarding the sufficiency of the data set used to support the BLA application.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 97% of claims this week
Replimune's stock price fell 64.29% to $1.70 per share following the announcement of the FDA's Complete Response Letter.
More negative than 94% of claims this week
Pomerantz LLP is investigating claims on behalf of Replimune investors regarding whether the company and certain officers or directors engaged in securities fraud or unlawful business practices.
More negative than 87% of claims this week
Which stocks this story touches
More negative than 99% of ticker scores this week
The company received an FDA CRL, saw its stock price crash by over 64%, and is now the subject of a securities fraud investigation.
More negative than 81% of ticker scores this week
The company is mentioned as the subject of an investigation into claims by investors.
More negative than 81% of ticker scores this week
The company is mentioned as the subject of an investigation into claims by investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
2h ago
+318.9%
Price is moving against the score
$20.65 vs $4.93 close before publication (May 14) · not market-adjusted
REPL chart →
